TAVR and Tricuspid - Cardiovascular Update

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

FEBRUARY 15, 2024

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

DAIC

APRIL 30, 2024

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR

TAVR Aortic valve Tricuspid Coronary Artery Bypass Graft

SAVR’s Value in the TAVR Era

CardiacWire

JANUARY 31, 2024

Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.

TAVR

TAVR Aortic valve Bicuspid/Mitral Aortic

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Greater Baseline TR Associated With Worse Outcomes After TAVR or Mitral TEER

American College of Cardiology

OCTOBER 21, 2024

Patients with moderate or severe tricuspid regurgitation (TR) prior to undergoing TAVR or mitral transcatheter edge-to-edge repair (TEER), when compared to patients with no or mild TR, were associated with worse health status and clinical outcomes, according to a study published in JACC: Cardiovascular Interventions.

TAVR

TAVR Bicuspid/Mitral Outcomes Tricuspid

Early experience with a novel transapical transcatheter aortic valve system in patients with severe aortic stenosis: a prospective, multicenter study

Frontiers in Cardiovascular Medicine

MARCH 20, 2025

All patients were pre-TAVR assessed by transthoracic echocardiography and computed tomography of the aortic valve (AV) and relevant left cardiac and vascular anatomy. Nanjing) to evaluate its safety and efficacy.Methods130 high risk patients with symptomatic severe AS from 11 institutions were treated with the novel Xcor system.

Aortic valve

Aortic valve Aortic Bicuspid/Mitral Stenosis

Edwards Lifesciences to Sell Critical Care to BD

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

Critical Care

Critical Care Tricuspid Innovation Bicuspid/Mitral

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

MARCH 15, 2024

Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease.

TAVR

TAVR Academic Education Cardiovascular Surgery

Early-Stage Results with Transcatheter Tricuspid-Valve Replacement

The New England Journal of Medicine

OCTOBER 29, 2024

Transcatheter aortic-valve replacement (TAVR) has been accepted as a reasonable alternative to surgical aortic-valve replacement for the treatment of.

Aortic valve

Aortic valve Tricuspid TAVR Aortic

FDA Approves TriClip; Fortified Eggs vs Cholesterol; Impella Maker Chided

Med Page Today

APRIL 2, 2024

(MedPage Today) -- Abbott said its TriClip transcatheter edge-to-edge repair system snagged FDA approval for treating for tricuspid regurgitation. Medtronic announced that the FDA approved the Evolut FX+ TAVR system, featuring a larger diamond.

Cholesterol

Cholesterol TAVR Tricuspid

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Open Heart

OCTOBER 19, 2022

Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aortic stenosis (AS) prior to transcatheter aortic valve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. after TAVR, were available from 247 patients (67.5%). ±15.8 ±15.1 to 94.8%)).

Aortic valve

Aortic valve Aortic Stenosis TAVR

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

European Journal of Heart Failure

FEBRUARY 26, 2025

Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

Blood Pressure

Blood Pressure Heart Failure Aortic valve TAVR

Transcatheter versus surgical valve replacement in patients with bicuspid aortic valves: an updated meta-analysis

The British Journal of Cardiology

FEBRUARY 20, 2024

We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. Single-arm studies, conference presentations, animal studies, and studies that involved patients with tricuspid aortic morphology were excluded.

Aortic valve

Aortic valve Bicuspid/Mitral Aortic TAVR

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

MARCH 15, 2024

Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease.

TAVR

TAVR Academic Education Cardiovascular Surgery

2023 STS Coding Workshop

Society of Thoracic Surgeons - Allied Health

NOVEMBER 15, 2022

hours total) Joseph Turek, MD, Jeffrey P.

Reimbursement

Reimbursement Cardiothoracic Document Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

TCT 2024’s Top TAVR Studies

CardiacWire

NOVEMBER 3, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8

TAVR

TAVR Embolism Interventional Cardiology Aortic

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

SAVR’s Value in the TAVR Era

Webinars

Greater Baseline TR Associated With Worse Outcomes After TAVR or Mitral TEER

Early experience with a novel transapical transcatheter aortic valve system in patients with severe aortic stenosis: a prospective, multicenter study

Edwards Lifesciences to Sell Critical Care to BD

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

Early-Stage Results with Transcatheter Tricuspid-Valve Replacement

FDA Approves TriClip; Fortified Eggs vs Cholesterol; Impella Maker Chided

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

Transcatheter versus surgical valve replacement in patients with bicuspid aortic valves: an updated meta-analysis

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

2023 STS Coding Workshop

Published Research

Published Research

TCT 2024’s Top TAVR Studies

Stay Connected